Scienture (SCNX, Financial) has announced that its U.S. Patent Nos. 11890273 and 12156869 have been officially listed by the U.S. Food and Drug Administration in the Approved Drug Products with Therapeutic Equivalence Evaluations. These patents pertain to their innovative product, Arbli, Oral Suspension at a concentration of 10mg/mL, approved under a New Drug Application. Both patents are set to expire in October 2041.
The patents titled “Losartan Liquid Formulations and Methods of Use” encapsulate stable liquid pharmaceutical compositions of Losartan. They also describe methods for administering these formulations to patients who require Losartan. This development reinforces Scienture's intellectual property rights and could provide a foundation for statutory exclusivity and market protection under the Hatch-Waxman Act.
